DEVELOPING ORAL BIOLOGICS THAT ACT ON CELLS IN THE SMALL INTESTINE WITH SYSTEMIC THERAPEUTIC EFFECTS
Cells in the small intestine play a central role in governing our immune, metabolic and neurological systems.
Our first product candidates are single strains of microbes selected for defined pharmacological properties.
Our therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic diseases and cancer.
About our science
Our Platform
- We have developed an integrated platform to develop oral biologics which harness the central role that cells in the small intestine play in governing our immune, metabolic and neurological systems.
- The efficiency of our platform has allowed us to produce, in a relatively short period of time, product candidates for a range of inflammatory diseases and cancer.
Our Portfolio
We currently have four product candidates: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer. We are also advancing additional oral biologics through preclinical development in other disease areas.
About our portfolioEvelo is led by a team with deep experience.
Our leadership team has founded, led, and grown transformative platform biotechnology companies. Our team has also developed and commercialized medicines that have impacted many lives.
About our teamSelect News
- EVELO BIOSCIENCES PRESENTS NEW PRECLINICAL DATA FOR ANTI-TUMOR EFFECTS OF ORALLY DELIVERED MICROBIAL EXTRACELLULAR VESICLES AT THE SITC 35TH ANNIVERSARY ANNUAL MEETING
Cambridge, MA - November 9, 2020 - EVELO BIOSCIENCES REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Cambridge, MA - October 29, 2020 - EVELO BIOSCIENCES TO HOST KEY OPINION LEADER DISCUSSION FOCUSED ON THE UNMET NEED IN PSORIASIS AND ATOPIC DERMATITIS AND THE POTENTIAL OPPORTUNITY FOR EDP1815
Cambridge, MA - October 15, 2020 - EVELO BIOSCIENCES COMPLETES ENROLLMENT IN PHASE 1B CLINICAL TRIAL COHORT EVALUATING EDP1815 IN ATOPIC DERMATITIS
Cambridge, MA - October 14, 2020
Select Press
- CREATING THE FUTURE OF MICROBIOME-BASED THERAPIES: SIMBA GILL ON THE LONG RUN
The Long Run Podcast with Luke Timmerman - November 13, 2020 - IN THE BATTLE AGAINST CANCER, MICROBES COULD BE THE ANSWER
WIRED Health - February 6, 2018 - NOT YOUR MOM'S PROBIOTIC: GOOGLE-BACKED EVELO TEAMS UP WITH MAYO CLINIC ON MICROBIOME DRUGS
ENPOINTS NEWS - November 16, 2017 - AFTER RAISING $100M, GOOGLE-BACKED EVELO LOOKS TO BLAZE A NEW TRAIL WITH MONOCLONAL MICROBIALS
ENDPOINTS NEWS - July 11, 2017
Relevant Publications
- HUMAN GUT-DERIVED COMMENSAL BACTERIA SUPPRESS CNS INFLAMMATORY AND DEMYELINATING DISEASE
Cell Reports - August 8, 2017 - MINING THE HUMAN GUT MICROBIOTA FOR IMMUNOMODULATORY ORGANISMS
Cell - February 23, 2017 - SUPPRESSION OF INFLAMMATORY ARTHRITIS BY HUMAN GUT‐DERIVED PREVOTELLA HISTICOLA IN HUMANIZED MICE
Arthritis & Rheumatology - June 23, 2016 - COMMENSAL BIFIDOBACTERIUM PROMOTES ANTITUMOR IMMUNITY AND FACILITATES ANTI–PD-L1 EFFICACY
Science - November 27, 2015
The destination for pioneers and adventurers
If you want to join an exceptional team and culture that is committed to driving profound benefits to patients and society, let us know.
Careers pageContact
620 Memorial Drive, 5th Floor
Cambridge, MA, 02139 USA
Hobday Building, The London BioScience Innovation Centre
2 Royal College Street, London, NW1 0NH, UK
For general inquiries contact:
info@evelobio.com
For media inquiries contact:
media@evelobio.com
For investor inquiries contact:
ir@evelobio.com